Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKR-2 (CYAD-01) with Preconditioning in r/r AML/MDS
NCT03466320Phase 2Completed
- Sponsor
- Celyad Oncology
- Start
- Sep 2018
- Primary completion
- Feb 2021
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of CAR-NKG2D in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Celyad Oncology. Started Sep 2018; status: completed.
02
Drugs
CAR-NKG2D
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03466320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466320.